1/2
Export Ready

SUNITCAP-SUNITINIB MALATE CAPSULES 50MG

Sold by RADHAKRUSHNA MEDICALS · Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

Price
Price on request
In stock
Minimum order: 1 Bottle

Export Snapshot

MOQ
1 Bottle
Lead time
On request
Packaging
Standard export packaging
Shelf life / longevity
As per product specification
HSN Code
30041090
Origin
India
Port of dispatch
On request
Export markets served
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
Values shown are for RADHAKRUSHNA MEDICALS.
Suitable for

Importers · Distributors · Wholesalers

Know your supplier

RADHAKRUSHNA MEDICALS is a Distributor, Exporter, Wholesaler based in Yavatmal Maharashtra India.

Yavatmal Dispatch on request Verified seller
RADHAKRUSHNA MEDICALS logo

Distributor, Exporter, Wholesaler · Yavatmal, Maharashtra, India

"Radhakrushna Medicals: Your Destination for Critical Care & Speciality Medicines. Surgical Suture Vaccines  "

Registered address: Yavatmal, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

Established
2022
Employees
1–10
GST
27AEMPT2491Q2ZF
IEC code
AEMPT2491Q
Export markets
United States flag US Philippines flag PH Smaller Territories of the UK flag XG United Kingdom flag GB Bangladesh flag BD +46 others
GlobalLinker Member Since
Feb 2026
Turnover
$50,000 - $250,000
Incorporation Type
On request
Product details

What are the specifications of this product?

Overview

Description SUNITCAP 50 mg contains Sunitinib malate, an oral targeted anticancer medicine. It is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks receptors involved in tumor growth, angiogenesis (blood vessel formation), and cancer cell survival, thereby slowing cancer progression.Uses Sunitinib is used in adults for the treatment of:1. Advanced / metastatic Renal Cell Carcinoma (RCC)2. Gastrointestinal Stromal Tumor (GIST)    – After failure or intolerance to imatinib3. Pancreatic Neuroendocrine Tumors (pNETs)    – Unresectable or metastatic, well-differentiated rx_imgPrescription Required

Product Description

Common side effects:

•   Fatigue, weakness

•   Diarrhea

•   Nausea and vomiting

•   Decreased appetite, weight loss

•   Hypertension

•   Hand–foot syndrome

•   Mouth ulcers (stomatitis)

•   Skin and hair color changes

Serious side effects:

•   Cardiac toxicity (reduced LVEF, heart failure)

•   Severe hypertension

•   Thyroid dysfunction (hypothyroidism)

•   Bleeding or thromboembolic events

•   Liver toxicity

 Regular monitoring of blood pressure, thyroid function, liver function, and cardiac status is mandatory.

Dosage
Dosage is based on indication and patient tolerance.

Standard dosing:

•   50 mg once daily for 4 weeks ON, 2 weeks OFF
    (One treatment cycle = 6 weeks)

Alternative dosing:

•   37.5 mg once daily continuously (commonly in pNETs)

    Dose reduction may be done using 25 mg or 12.5 mg capsules if toxicity occurs.

Description provided by RADHAKRUSHNA MEDICALS.

Specifications

Dosage Form Capsule
Strength 50mg
Route of Administration Oral
Indications Advanced/Metastatic Renal Cell Carcinoma, GIST post-imatinib failure, Unresectable/Metastatic Pancreatic Neuroendocrine Tumors
Packaging Unit Bottle
Storage Conditions Store at room temperature, protect from moisture
Prescription Status Prescription required
Treatment Cycle 6 weeks (4 weeks on drug, 2 weeks off) or continuous dosing
Side Effects Fatigue, diarrhea, nausea, hypertension, cardiac toxicity, thyroid dysfunction
Monitoring Requirements Blood pressure, liver function, thyroid function, cardiac status

Use cases

Category Pharmaceuticals > Oncology > Targeted Cancer Therapies > Tyrosine Kinase Inhibitors
Primary application Wholesale, distribution, and international sourcing
Brand Not specified
Product type Product

Logistics & handling

Lead time On request
Packaging As per buyer requirement
Storage condition As recommended by supplier
Origin India
Form As listed by supplier

Commercials (this seller)

Minimum order 1 Bottle
Lead time On request
Payment terms As per negotiated commercial agreement.
Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing SUNITCAP-SUNITINIB MALATE CAPSULES 50MG. Answers compiled from verified sellers' commercial terms and platform data.

Q: What cancer types is SUNITCAP-Sunitinib Malate Capsules 50mg primarily used to treat?
A: SUNITCAP is primarily indicated for advanced or metastatic Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumors (GIST) after imatinib failure, and unresectable or metastatic Pancreatic Neuroendocrine Tumors (pNETs).
Q: What is the standard dosing regimen for SUNITCAP 50mg capsules?
A: The standard dosing is 50mg once daily taken orally for 4 weeks followed by a 2-week drug-free period, making one complete treatment cycle of 6 weeks.
Q: Are there any mandatory monitoring requirements during treatment with SUNITCAP?
A: Yes, patients require regular monitoring of blood pressure, cardiac function, thyroid hormones, and liver function to detect and manage potential side effects.
Q: Can the dose of SUNITCAP be adjusted if side effects manifest?
A: Yes, dose reduction to 25mg or 12.5mg capsules can be implemented based on patient tolerance and toxicity.
Q: Is a prescription needed to order SUNITCAP-Sunitinib Malate Capsules 50mg?
A: Yes, this is a prescription-only anticancer medication and should be dispensed accordingly.
Question not answered? Ask sellers directly — typical response within 4 hours.
SUNITCAP-SUNITINIB MALATE CAPSULES 50MG
SUNITCAP-SUNITINIB MALATE CAPSULES 50MG
Price on request · MOQ 1Bottle